Skip to main content
Caplight Logo









Cleveland Diagnostics

Cleveland Diagnostics

Private
Cleveland, OhioHealthcare & Life Scienceshttps://www.clevelanddx.com/

Last Round

Series E

Jan 17, 2024

Est. Valuation

$13.2M

Total Funding Raised

$77M

Company Overview

Cleveland Diagnostics is a biotechnology company that develops non-invasive diagnostic tests for early cancer detection using a proprietary platform that analyzes protein structural changes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

prostate cancer detectionIsoPSAliquid biopsyin vitro diagnosticIVDprostate cancer screeningbiotech diagnosticscancer biomarkerPSA testprecision oncologyclinical laboratorynon-invasive diagnosticsurology diagnosticsprotein-based diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cleveland Diagnostics Comparables

Compare Cleveland Diagnostics with similar companies based on industry and business-model similarity.

Cleveland Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LynxDx
83%
MDxHealth
81%
MiRNA Scientific
80%

Cleveland Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series EJan 17, 2024
Convertible DebtFeb 9, 2021
Convertible DebtNov 28, 2017
VC RoundNov 21, 2016
VC RoundMar 20, 2015

Key People

Founding team and executive leadership

Michael Iskra

Chief Executive Officer

Executive Team

Cleveland Diagnostics Investors

Notable investors and investment history

Cleveland Diagnostics investors
InvestorRounds
Serial Stage Venture PartnersSeries E
Genomic HealthConvertible Debt
Cleveland Clinic VenturesConvertible Debt, Series E
LYFE CapitalConvertible Debt
Symbiotic CapitalSeries E
Novo HoldingsSeries E

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    IsoPSA Test for Prostate Cancer gains FDA approval.

  • Mar 1, 2026

    Launched FDA-approved IsoPSA Test for Prostate Cancer nationwide.

Cleveland Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cleveland Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cleveland Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCleveland, Ohio
Employee Range108
Year Founded2013
Last FundingJan 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?